| Literature DB >> 28318889 |
Eli Vlaisavljevich1, Gabe Owens2, Jonathan Lundt3, Dejan Teofilovic4, Kimberly Ives3, Alexander Duryea4, Jim Bertolina4, Theodore H Welling5, Zhen Xu2.
Abstract
This study investigates the safety profile for use of histotripsy, a non-invasive ultrasonic ablation method currently being developed for the treatment of liver cancer, for liver ablation in an in vivo porcine model. Histotripsy treatments were applied to the liver and hepatic veins of 22 porcine subjects, with half of the subjects receiving systemic heparinization. Vital signs (heart rate, blood pressure, temperature, electrocardiogram and SpO2) were monitored throughout the procedure and for 1 h post-treatment. Blood was drawn at six points during the experiment to analyze blood gases, liver function and free hemoglobin levels. All treatments were guided and monitored by real-time ultrasound imaging. After treatment, the tissue was harvested for histological analysis. Results indicated that histotripsy generated well-defined lesions inside the liver and around the treated hepatic veins of all subjects in both treatment groups. Vital signs and blood analysis revealed that animals responded well to histotripsy, with all animals surviving the treatment. One animal in the non-heparinized group had a transient increase in pH and decreases in blood pressure, heart rate and PCO2 during the 15-min vessel treatment, with these changes returning to baseline levels soon after the treatment. Overall, the results indicate that histotripsy can safely be performed on the liver without the need for systemic heparinization, even in regions containing large hepatic vessels, supporting its future use for the treatment of liver cancer.Entities:
Keywords: Ablation; Cavitation; Histotripsy; Liver; Non-invasive; Safety; Ultrasound
Mesh:
Year: 2017 PMID: 28318889 DOI: 10.1016/j.ultrasmedbio.2017.01.016
Source DB: PubMed Journal: Ultrasound Med Biol ISSN: 0301-5629 Impact factor: 2.998